| Literature DB >> 27600391 |
Qi Wang1,2, Haibo Ding1,2, Junjie Xu1,2, Wenqing Geng1,2, Jing Liu1,2, Xiaolin Guo1,2, Jing Kang1,2, Xiaolin Li1,2, Yongjun Jiang1,2, Hong Shang3,4.
Abstract
BACKGROUND: Dyslipidemia is commonly seen in human immunodeficiency virus (HIV) infected patients. Understanding the risk factors of abnormal lipid profiles is urgent for proposing targeted approaches to prevention. Our objective was to assess the incidence and associated factors of abnormal lipid profiles and atherogenic index of plasma (AIP) among antiretroviral therapy (ART) naïve men who have sex with men (MSM) acute HIV infection (AHI) and chronic HIV infection (CHI) patients in China.Entities:
Keywords: Atherogenic index of plasma (AIP); Dyslipidemia; Human immunodeficiency virus (HIV); Lipids
Mesh:
Substances:
Year: 2016 PMID: 27600391 PMCID: PMC5012071 DOI: 10.1186/s12944-016-0297-1
Source DB: PubMed Journal: Lipids Health Dis ISSN: 1476-511X Impact factor: 3.876
Demographic and clinical characteristics of the no-HIV and AHI and CHI participants
| Variables | No-HIV | AHI | CHI |
|---|---|---|---|
| Age (years) | 32.2 ± 9.0 | 31.5 ± 8.6 | 33.8 ± 6.2 |
| Height (cm) | 174.0 ± 5.1 | 173.9 ± 4.6 | 174.5 ± 6.0 |
| Weight (kg) | 65.9 ± 11.4 | 63.9 ± 8.5 | 66.1 ± 10.9 |
| BMI (kg/m2) | 21.8 ± 3.6 | 21.1 ± 2.6 | 21.7 ± 3.4 |
| History of smoking, | 38 (38.0) | 29 (26.4) | 37 (33.6) |
| History of alcohol, | 45 (45.0) | 44 (40.0) | 52 (47.3) |
| SBP (mmHg) | 120.0 (114.6–122.7) | 114.5 (112.0–120.0) | 120.0 (116.0–126.1) |
| DBP (mmHg) | 80.0 (79.0–84.2) | 76.0 (72.0–78.2) | 83.6 (79.1–88.0) |
| Hypertension, | 17 (17.0) | 10 (9.1) | 19 (17.3) |
| FBG (mmol/L) | 4.59 (4.21–5.01) | 4.88 (4.47–5.27) | 5.13 (4.76–5.53)a |
| Estimated infection (days) | NA | 65.0 (38.5–106.0)b | 631.0 (133.0–1135.0) |
| CD4 cell count (cells/mm3) | NA | 404.0 (281.5–531.5)b | 173.0 (113.3–243.2) |
| HIV RNA (log10 copies/ml) | NA | 4.83 (4.43–5.27) | 4.66 (4.27–4.88) |
No-HIV HIV negative control, AHI acute HIV infection group, CHI chronic HIV infection group, n indicates the number of participants, BMI body mass index, SBP brachial systolic blood pressure, DBP brachial diastolic blood pressure, FBG fasting blood glucose
Data are expressed as mean with ± standard error of mean, geometric mean with 5th and 95th percentile intervals, n or % of n
NA None applicable
a p value < 0.05 between CHI and AHI, CHI and no-HIV
b p value < 0.05 between AHI and CHI
Lipid profiles and AIP of the no-HIV, AHI and CHI participants
| Variables | No-HIV | AHI | CHI |
|---|---|---|---|
| TG (mmol/L) | 1.17 (0.76–1.67) | 1.11 (0.89–1.52) | 1.06 (0.79–1.42) |
| TC (mmol/L) | 4.49 ± 0.91a | 3.90 ± 0.73 | 3.72 ± 0.74 |
| HDL-C (mmol/L) | 1.19 ± 0.29a | 1.00 ± 0.25 | 1.01 ± 0.30 |
| LDL-C (mmol/L) | 2.75 ± 0.78a | 2.11 ± 0.57 | 2.22 ± 0.58 |
| TC/HDL-C | 3.79 (3.18–4.54) | 3.95 (3.45–4.57) | 3.67 (3.19–4.29) |
| Hypertriglyceridemia, | 23 (23.0) | 17 (15.5) | 22 (20.0) |
| Hypercholesterolemia, | 21 (21.0)a | 7 (6.4) | 3 (2.7) |
| Low HDL-C, | 17 (17.0)a | 37 (33.6) | 44 (40.0) |
| High LDL-C, | 16 (16.0)a | 2 (1.8) | 2 (1.8) |
| High TC/HDL-C ratio, | 16 (16.0) | 16 (14.5) | 15 (13.6) |
| Dyslipidemia, | 44 (44.0) | 51 (46.4) | 52 (47.3) |
| AIP | −0.04 (−0.21–0.22) | 0.08 (−0.05–0.20)b | 0.03 (−0.17–0.23) |
| AIP > 0.1, | 38 (38.0) | 51 (46.4) | 48 (43.6) |
No-HIV HIV negative control, AHI acute HIV infection group, CHI chronic HIV infection group, TG triglycerides, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, AIP the atherogenic index of plasma
a p value < 0.05 between no-HIV and AHI, no-HIV and CHI
b p value < 0.05 between no-HIV and AHI
Fig. 1Incidence of undesirable lipid concentrations among the no-HIV, AHI and CHI group. No-HIV, HIV negative control ; AHI, acute HIV infection group; CHI, chronic HIV infection group; TG, triglycerides; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; AIP, the atherogenic index of plasma
Pearson correlation coefficients between AIP and clinical and laboratory factors in the no-HIV group (Model 1), and in the HIV group (Model 2)
| Model 1 | Model 2* | |||
|---|---|---|---|---|
| Factors | R |
| R |
|
| TG (mmol/l) | 0.915 | <0.001 | 0.843 | <0.001 |
| TC (mmol/l) | 0.258 | 0.009 | −0.015 | 0.821 |
| HDL-C (mmol/l) | −0.680 | <0.001 | −0.653 | <0.001 |
| LDL-C (mmol/l) | 0.245 | 0.014 | 0.021 | 0.751 |
| FBG (mmol/l) | 0.086 | 0.397 | 0.049 | 0.473 |
| Age (years) | 0.172 | 0.087 | 0.124 | 0.066 |
| Height (cm) | 0.002 | 0.987 | 0.001 | 0.990 |
| Weight (kg) | 0.221 | 0.027 | 0.219 | 0.001 |
| BMI (kg/m2) | 0.236 | 0.018 | 0.233 | <0.001 |
| SBP (mmHg) | 0.155 | 0.123 | 0.095 | 0.162 |
| DBP (mmHg) | 0.201 | 0.045 | 0.118 | 0.082 |
| CD4 cell count (cells/mm3) | -- | -- | −0.063 | 0.364 |
| HIV RNA (log10 copies/ml) | -- | -- | 0.151 | 0.029 |
Model 2*, AHI and CHI patients were all included
TG triglycerides, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, FBG fasting blood glucose, BMI body mass index, SBP brachial systolic blood pressure, DBP brachial diastolic blood pressure
Factors correlated with AIP after controlling for potential confounders
| No-HIV | AHI | CHI | Total* | |||||
|---|---|---|---|---|---|---|---|---|
| β ± SE |
| β ± SE |
| β ± SE |
| β ± SE |
| |
| AHI versus HIV-negative | --- | --- | --- | --- | --- | --- | 0.029 ± 0.012 | 0.015 |
| CHI versus HIV-negative | --- | --- | --- | --- | --- | --- | --- | --- |
| Age (years) | 0.001 ± 0.001 | 0.322 | −0.001 ± 0.001 | 0.209 | −0.001 ± 0.002 | 0.747 | −0.001 ± .001 | 0.343 |
| Smoker versus nonsmoker | −0.004 ± 0.022 | 0.841 | 0.009 ± 0.010 | 0.374 | 0.020 ± 0.022 | 0.369 | 0.013 ± 0.013 | 0.319 |
| Drinker versus nondrinker | 0.009 ± 0.020 | 0.653 | −0.012 ± 0.009 | 0.177 | −0.033 ± 0.022 | 0.137 | −0.011 ± 0.012 | 0.342 |
| BMI (kg/m2) | −0.001 ± 0.003 | 0.690 | 0.001 ± 0.002 | 0.520 | 0.000 ± 0.003 | 0.963 | 0.003 ± 0.002 | 0.139 |
| TG (mmol/L) | 0.245 ± 0.013 | <0.001 | 0.353 ± 0.010 | <0.001 | 0.214 ± 0.018 | <0.001 | 0.273 ± 0.009 | <0.001 |
| TC (mmol/L) | 0.039 ± 0.013 | 0.003 | --- | --- | 0.138 ± 0.049 | 0.006 | --- | --- |
| HDL-C (mmol/L) | −0.413 ± 0.041 | <0.001 | −0.417 ± 0.018 | <0.001 | −0.638 ± 0.066 | <0.001 | −0.444 ± 0.023 | <0.001 |
| LDL-C (mmol/L) | --- | --- | --- | --- | 0.100 ± 0.048 | 0.040 | --- | --- |
| FBG (mmol/L) | --- | --- | --- | --- | --- | --- | --- | --- |
| SBP (mmHg) | --- | --- | --- | --- | --- | --- | --- | --- |
| DBP (mmHg) | --- | --- | --- | --- | --- | --- | --- | --- |
| CD4 cell count (cells/mm3) | --- | --- | --- | --- | --- | --- | --- | --- |
| HIV RNA (log10 copies/ml) | --- | --- | --- | --- | --- | --- | --- | --- |
No-HIV HIV negative control, AHI acute HIV infection group, CHI chronic HIV infection group, Total*, no-HIV, AHI and CHI participants were all included; BMI body mass index, TG triglycerides, TC total cholesterol, HDL-c high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, FBG fasting blood glucose, SBP brachial systolic blood pressure, DBP brachial diastolic blood pressure
The β values are the multivariate regression unstandardized coefficients
SE, standard error of mean